DAX24.915 +0,3%Est505.985 -0,4%MSCI World4.343 -0,1%Top 10 Crypto8,7200 +5,5%Nas22.547 -0,2%Bitcoin57.895 -0,2%Euro1,1863 -0,1%Öl67,75 +0,3%Gold5.043 +2,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens 723610 Rheinmetall 703000 Siemens Energy ENER6Y Deutsche Telekom 555750 SAP 716460 Amazon 906866 NVIDIA 918422 Mercedes-Benz Group (ex Daimler) 710000 Lufthansa 823212 Microsoft 870747 Deutsche Bank 514000 BASF BASF11 DroneShield A2DMAA Allianz 840400 Bayer BAY001
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach Inflationsdaten: US-Börsen letztlich uneins -- DAX geht etwas fester ins Wochenende -- Amazon im Bärenmarkt -- Delivery Hero, pbb, Siemens, RWE, Rivian, Adyen, Apple, Arista im Fokus
Top News
Online Broker Vergleich - die besten Aktiendepots und Trading-Plattformen im Test Online Broker Vergleich - die besten Aktiendepots und Trading-Plattformen im Test
Bilanzen & Termine: Tesla, NVIDIA, Apple, Amazon & Co. - Ergebnisse der Tech-Riesen in der aktuellen Saison Bilanzen & Termine: Tesla, NVIDIA, Apple, Amazon & Co. - Ergebnisse der Tech-Riesen in der aktuellen Saison
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Syndax Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
17,40 EUR -0,50 EUR -2,79 %
BMN
20,50 USD -0,65 USD -3,07 %
nachbörslich
BTT
Syndax Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.1,55 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2AFL6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS87164F1057

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSNDX

Syndax Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireSyndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
PR NewswireSyndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
PR NewswireSyndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
PR NewswireSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
PR NewswireSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
PR NewswireSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
PR NewswireSyndax Announces Appointment of Steven Closter as Chief Commercial Officer
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences
PR NewswireSyndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireSyndax Highlights Recent Updates and Anticipated 2024 Milestones
PR NewswireSyndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting
PR NewswireSyndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
PR NewswireSyndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting
PR NewswireSyndax Announces Participation at Stifel Healthcare Conference
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting
PR NewswireSyndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting
PR NewswireSyndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023
PR NewswireSyndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
PR NewswireSyndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis
PR NewswireSyndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation at the Citi 18th Annual BioPharma Conference
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023
PR NewswireSyndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals News

Syndax Pharmaceuticals News: auf dieser Seite finden Sie alle Syndax Pharmaceuticals News und Nachrichten zur Syndax Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Syndax Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Syndax Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.